title: Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.
abstract: One hundred sixty-five patients were randomized to receive either interferon alfa-n1 (Wellferon; Burroughs Wellcome Co, Research Triangle Park, NC) alone or with vinblastine. An initial six-cycle induction treatment consisted of interferon given at daily doses of 3, 5, 20, 20, and 20 x 10(6) U/m2 every 2 weeks. Vinblastine at a dose of 10 mg/m2 (later decreased to 5 mg/m2) was given on day 1 of alternate cycles. Toxicities were generally well tolerated. The overall response rate was 10% with no significant difference between treatment arms. Survival was also not significantly different for the arms. A small subset of patients (16) with metastases only to the lungs had a high complete response (CR) and partial response (PR) rate of 44%. Responses were durable, and overall survival of this group was much better than that of the other patients.
authors.affiliation: University of New Mexico, Albuquerque.
authors.forename: J A
authors.initials: JA
authors.lastname: Neidhart
authors.forename: S A
authors.initials: SA
authors.lastname: Anderson
authors.forename: J E
authors.initials: JE
authors.lastname: Harris
authors.forename: J J
authors.initials: JJ
authors.lastname: Rinehart
authors.forename: J
authors.initials: J
authors.lastname: Laszlo
authors.forename: F H
authors.initials: FH
authors.lastname: Dexeus
authors.forename: L H
authors.initials: LH
authors.lastname: Einhorn
authors.forename: D L
authors.initials: DL
authors.lastname: Trump
authors.forename: P W
authors.initials: PW
authors.lastname: Benedetto
authors.forename: R L
authors.initials: RL
authors.lastname: Tuttle
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy; D008297:Male; D012074:Remission Induction; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D007370:Interferon Type I; D014747:Vinblastine